TrialBlood2024

Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.

Andrew D Leavitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.